Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):

[ ]

Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging
growth company [ ]

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Cautionary
Note on Forward-Looking Statements

This
Current Report on Form 8-K (this “Report”) and any related statements of representatives and partners of the Company
contain, or may contain, among other things, certain “forward-looking statements” within the meaning of Section 27A
of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of
1934, as amended (the “Exchange Act”). Such forward-looking statements involve significant risks and uncertainties.
Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections,
expectations and intentions and other statements identified by words such as “projects,” “may,” “will,”
“could,” “would,” “should,” “believes,” “expects,” “anticipates,”
“estimates,” “intends,” “plans,” or similar expressions. These statements are based upon the
current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including
those detailed in the Company’s filings with the Securities and Exchange Commission (the “SEC”). Actual results
may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain
risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control).
The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by applicable law.

Item
7.01 Regulation FD Disclosure.

On April 26, 2018,
PositiveID Corporation (“PositiveID”) issued a press release providing an update on the status of its progress and
goals for the remainder of 2018. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and incorporated by
reference herein.

The press release contains
forward-looking statements involving risks and uncertainties, both known and unknown, that may cause actual results to differ
materially from those indicated. Actual results may differ materially due to a number of factors, including those factors discussed
in the press release, and other factors discussed in the Company’s filings with the Securities and Exchange Commission,
including its report on Form 10-K for the year ended December 31, 2017, and its most recent Quarterly Report on Form 10-Q for
the quarter ended September 30, 2017, and subsequent filings. Any forward-looking statements included in the press release are
as of April 26, 2018, and the Company does not intend to update them if its views later change, except as may be required
by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent
to April 26, 2018.

The
information referenced under Item 7.01 (including Exhibit 99.1 referenced in Item 9.01 below) of this Current Report on Form 8-K
is being “furnished” under “Item 7.01. Regulation FD Disclosure” and, as such, shall not be deemed to
be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that Section. The information set forth in this Current Report on Form
8-K (including Exhibit 99.1referenced in Item 9.01 below) shall not be incorporated by reference into any registration statement,
report or other document filed by PositiveID pursuant to the Securities Act of 1933, as amended (the “Securities Act”),
except as shall be expressly set forth by specific reference in such filing. PositiveID does not undertake to update the information
as posted on its website; however, it may post additional information included in future press releases and Forms 8-K, as well
as posting its periodic Exchange Act reports.

Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.

POSITIVEID
CORPORATION

Date:
April 26, 2018

By:

/s/
William J. Caragol

Name:

William
J. Caragol

Title:

Chief
Executive Officer

PositiveID’s
Chairman and CEO Addresses Stockholders

DELRAY BEACH, FL, April 26, 2018 —
PositiveID Corporation (“PositiveID” or “Company”) (OTC: PSIDD), a life sciences company focused on detection
and diagnostics, announced today that its Chairman and CEO, William J. Caragol, has issued a letter to stockholders:

Dear
Fellow Stockholders,

This
letter is intended to explain our recent reverse stock split and discuss the value of this important move. While we had hoped
to effect the reverse split simultaneous with a broader recapitalization of the Company we needed to take this action now in order
to continue to advance our development and commercialization initiatives.

I
understand the reverse split may be viewed negatively, but I strongly believe the assets we own have far greater value than our
capital structure is allowing and by continuing to push ahead we will be able to realize that value in the form of new strategic
partners, long-term capital, commercial, and government business for our diverse set of disruptive assets in on-site pathogen
detection, advanced clinical thermometry, and mobile labs.

In
prior communications and filings, we have discussed our strategy to unlock our asset value
through strategic partnering and we
want to update stockholders on that progress. Note that the progress update below is preliminary, and something we would not normally
discuss. In light of the reverse split, however, we thought it was important to provide this information to our stockholders.

Here
is the status of our progress and goals for the remainder of 2018:

FireflyDX

We
are currently working with several potential partners to fund the remaining testing and development of our portable pathogen detection
products, the FireflyDX-Portable and FireflyDX-Handheld. We have two potential transactions in negotiation phases.

The
first is a substantial exclusive license with a North American partner for a vertical market in the broader agricultural testing
space, which is expected to reach $7 billion by 2024 due primarily to pathogen testing and contamination testing. In the second
case, we have signed an MOU and are in advanced discussions with an international entity for a potential strategic collaboration
and direct investment into our ExcitePCR subsidiary to bring the FireflyDX product line to a major international market.

Under
either scenario, we expect to be able to raise the necessary capital to bring the FireflyDX-Portable to commercialization. Once
that occurs, we believe we will have crossed the most critical hurdle in achieving long-term success for ExcitePCR, as we anticipate
the demand that will be created by the FireflyDX-Portable will lead to the full funding and commercialization of the FireflyDX-Handheld.
Importantly, these strategic transactions would lead to significant investment/license into ExcitePCR, not the sale of ExcitePCR.
PositiveID and its shareholders would own a large percentage of a capitalized ExcitePCR.

We
specialize in mobile clinical innovation and we are pleased with the direction of these discussions and qualifications of the
potential partners. We also have great confidence in the disruptive potential of our patented pathogen detection technology in
many fields including infectious disease detection, human clinical, food safety, hospital and biological warfare.

We
look forward to keeping shareholders updated as we advance these initiatives.

Caregiver

We
recently announced a large order by a global healthcare company for our new infrared Caregiver® thermometer with Bluetooth.
We expect in the next couple months to announce a strategic agreement with a global medical technology company for enhanced patient
monitoring.

The
500-unit order referenced above, which is expected to be the first of many pending the successful launch of our customer’s
new product line, should help propel the growth and market adoption of our Caregiver product.

Sales
of the original Caregiver thermometer also continue to grow. Industry awareness of its unique features and advantages is growing
as a result of successful marketing campaigns and we are confident that as more clinical professionals become accustomed to the
ease-of-use benefits of non-contact thermometry, demand will grow, and sales will expand as the global temperature monitoring
market is forecast to surpass $3 billion by 2022. We receive very positive feedback from those who try Caregiver and have multiple
evaluations underway at hospitals throughout the country.

E-N-G
Mobile Systems

We
continue to hold a significant equity interest in E-N-G Mobile Systems (“ENG”), owning 24% of its capital stock. Though
we will no longer consolidate the financial results of this business, we will still benefit from its growth and success.

Last
month, we announced that ENG received a purchase order for a highly complex vehicle totaling approximately $1 million. ENG has
built a name for itself in the mobile lab and specialty vehicle business and works with extremely high-profile customers, including
Fortune 100 companies.

Looking
Ahead

It
is our intention, upon the success of closing one or both strategic deals for FireflyDX discussed above, to restructure our convertible
debt and replace such debt with long-term equity. This would then allow us to seek to acquire additional complementary intellectual
property or products to continue to grow and diversify PositiveID. However, for now we are extremely focused on our immediate
goals. I know for investors it has been a long and bumpy ride, and I assure you we will continue our mission to maximize the value
of our assets. I thank you for your continued support.

Yours
truly,

William
J. Caragol

About
PositiveID Corporation

PositiveID
Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological
detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and
performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory
market and homeland security. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with
PositiveID on Twitter, Facebook or LinkedIn.

Statements
about PositiveID’s future expectations, including the likelihood that the Company will continue to advance its development
and commercialization initiatives; the likelihood that by continuing to push ahead the Company will be able to realize the value
of its assets in the form of new strategic partners, long-term capital, commercial, and government business; the likelihood that
the agricultural testing space is expected to reach $7 billion by 2024 due primarily to pathogen testing and contamination testing;
the likelihood that under either potential transaction for FireflyDX, the Company expects to be able to raise the necessary capital
to bring the FireflyDX-Portable to commercialization; the likelihood that once that occurs, the Company will have crossed the
most critical hurdle in achieving long-term success for ExcitePCR; the likelihood that the demand that will be created by the
FireflyDX-Portable will lead to the full funding and commercialization of the FireflyDX-Handheld; the likelihood that these strategic
transactions would lead to significant investment/license into ExcitePCR, not the sale of ExcitePCR; the likelihood that PositiveID
and its shareholders would own a large percentage of a capitalized ExcitePCR; the likelihood that the Company’s patented
pathogen detection technology has disruptive potential in many fields including infectious disease detection, human clinical,
food safety, hospital and biological warfare; the likelihood that the Company will keep shareholders updated as it advances these
initiatives; the likliehood that in the next couple months the Company will announce a strategic agreement with a global medical
technology company for enhanced patient monitoring; the likelihood that the 500-unit order for Caregiver with Bluetooth, which
is expected to be the first of many pending the successful launch of our customer’s new product line, should help propel
the growth and market adoption of our Caregiver product; the likelihood that as more clinical professionals become accustomed
to the ease-of-use benefits of non-contact thermometry, demand will grow, and sales will expand; the likelihood that the global
temperature monitoring market is forecast to surpass $3 billion by 2022; the likelihood that the Company will still benefit from
ENG’s growth and success; the likelihood that it is the Company’s intention, upon the success of closing one or both
strategic deals for FireflyDX discussed above, to restructure its convertible debt and replace such debt with long-term equity;
the likelihood that this restructuring would then allow the Company to seek to acquire additional complementary intellectual property
or products to continue to grow and diversify PositiveID; the likelihood that the Company will continue its mission to maximize
the value of its assets; constitute “forward-looking statements” within the meaning of Section 27A of the Securities
Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform
Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID’s
actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s
ability to raise capital; the Company’s ability to fight litigation; the Company’s ability to fund the testing and
development of the FireflyDX product line; the Company’s ability to enter into a strategic partnership or partnerships for
FireflyDX; the Company’s ability to sell units of its Caregiver thermometer and Caregiver thermometer with Bluetooth. Additional
information about these and other factors that could affect the Company’s business is set forth in the Company’s various
filings with the Securities and Exchange Commission, including those set forth in the Company’s 10-K filed on April 2, 2018,
and 10-Qs filed on November 13, 2017, August 14, 2017, and May 15, 2017, under the caption “Risk Factors.” The Company
undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances
after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.